{"id":246,"date":"2020-07-23T14:10:17","date_gmt":"2020-07-23T18:10:17","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=246"},"modified":"2020-07-23T14:10:17","modified_gmt":"2020-07-23T18:10:17","slug":"discussion-of-nondrug-cbd-products-omitted-on-new-fda-draft-guidance-on-cannabis-related-clinical-research","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/07\/23\/discussion-of-nondrug-cbd-products-omitted-on-new-fda-draft-guidance-on-cannabis-related-clinical-research\/","title":{"rendered":"Discussion of Nondrug CBD Products Omitted on New FDA Draft Guidance on Cannabis-Related Clinical Research"},"content":{"rendered":"

On July 21, 2020, the U.S. Food & Drug Administration (FDA) issued draft guidance outlining the agency\u2019s current thinking on the development of drugs containing cannabis or cannabis-derived compounds. The new guidance is disappointing to many in the cannabis industry because it does not provide insight into the FDA\u2019s views on the marketing of nondrug, hemp-derived CBD products.<\/p>\n

To read the full text of this Duane Morris\u00a0Alert<\/em>, please\u00a0visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

On July 21, 2020, the U.S. Food & Drug Administration (FDA) issued draft guidance outlining the agency\u2019s current thinking on the development of drugs containing cannabis or cannabis-derived compounds. The new guidance is disappointing to many in the cannabis industry because it does not provide insight into the FDA\u2019s views on the marketing of nondrug, … <\/p>\n

Continue reading “Discussion of Nondrug CBD Products Omitted on New FDA Draft Guidance on Cannabis-Related Clinical Research”<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[360,491,490,29,419,492],"ppma_author":[521],"class_list":["post-246","post","type-post","status-publish","format-standard","hentry","category-general","tag-cbd","tag-draft-guidance","tag-drugs","tag-fda","tag-hemp","tag-u-s-food-and-drug-administration"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=246"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/246\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=246"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}